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Background: The estimation of an effect size is an important step in designing an adequately powered,
feasible clinical trial intended to change clinical practice. During the planning phase of VA Cooperative
Study #590, “Double-Blind Placebo-Controlled Study of Lithium for Preventing Repeated Suicidal Self-
Directed Violence in Patients with Depression or Bipolar Disorder (Liþ),” it was not clear what effect
size would be considered large enough to inﬂuence prescribing behavior among practicing clinicians.
Methods: We conducted an online survey of VA psychiatrists to assess their interest in the study
question, their clinical experience with lithium, and their opinion about what suicide reduction rate
would change their prescribing habits. The 9-item survey was hosted on SurveyMonkey© and VA psy-
chiatrists were individually emailed an invitation to complete an anonymous online survey. Three email
waves were sent over three weeks.
Results: Overall, 862 of 2713 VA psychiatrists (response rate ¼ 31.8%) responded to the anonymous
survey. 74% of the respondents would refer a patient to the proposed trial, 9% would not, and 17% were
unsure. Presented with suicide reduction rates in 10% increments ranging from 10 to 100%, 61% of re-
spondents indicated that they would use lithium if suicide attempts were reduced by at least 40%; 83%
would use lithium if it reduced attempts by at least 50%.
Conclusions: Even with the limitations of response bias and the reliability of responses on future pre-
scribing behavior, a survey of potential users of a clinical trial's results offers a convenient, empirical
method for determining and justifying clinically relevant effect sizes.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Randomized controlled trials face numerous challenges to
complete successfully [1,2]. Thoughtful preetrial planning is
necessary to determine the feasibility and to balance rigor, rele-
vance, and the resources available. The estimation of an effect size
is an important step in designing an adequately powered, feasible
clinical trial that has the potential to change clinical practice and to
improve patient outcomes.Epidemiology and Research
rogram Coordinating Center
tington Avenue (151-MAV),
rrington).
access article under the CC BY-NCThe Veterans Affairs Cooperative Studies Program (CSP) has
unique characteristics that make investigator-initiated multicenter
studies possible: an integrated healthcare system, a large stable
patient population, national databases, the oldest functioning
universal electronic medical record, core infrastructure with sta-
tistical, epidemiological, pharmaceutical, and health economics
expertise, and resources for planning studies [3]. During the plan-
ning phase of CSP #590, “Double-Blind Placebo-Controlled Study of
Lithium for Preventing Repeated Suicidal Self-Directed Violence in
Patients with Depression or Bipolar Disorder (Liþ),” a multi-center
study that has since been funded by the Veterans Affairs Cooper-
ative Studies Program, there was a lack of agreement among ex-
perts and outside consultants on whether there was sufﬁcient
support for the proposed study in the ﬁeld. In addition, it was not
clear what effect size would be considered large enough to-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Provider survey response rate over time.
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response, we designed a provider survey to address these concerns
from the largest number of potential users of the trial results.
CSP#590 would be the ﬁrst adequately powered randomized clin-
ical trial to evaluate the effectiveness of lithium in preventing ep-
isodes of suicidal self-directed violence.
The survey was intended to address three primary goals. The
ﬁrst was to understand current experience and practice with
regards to lithium; the second was to see whether psychiatrists
would be supportive of randomizing their patients to lithium or
placebo and endorse the study design; and the third goal was to
determine what effect size would be considered large enough to
inﬂuence prescribing behavior among practicing psychiatrists.
2. Methods
2.1. Overview of survey design
The study team developed a nine-item survey to address the
three major goals outlined above (see Appendix A for survey
questions). Before conducting the survey, we had extensive
consultation with our Quality Assurance department and the
Institutional Review Board (IRB) at VA Boston Healthcare System.
Wewere advised that IRB approval was not necessary as the survey
was a preparatory to research activity and meant to facilitate the
planning of a study. After completion of the survey, we realized that
the methods and results may be of interest to the scientiﬁc com-
munity andwe again sought guidance from the local VA IRB. The VA
Boston Healthcare System IRB Committee certiﬁed that the pro-
vider survey met all published guidelines for “exempt research” as
deﬁned in 38 CFR x16.101 and Veterans Health Administration
(VHA) Handbook 1200.05 [4,5]. The VA Boston Healthcare System
Research and Development Committee subsequently approved this
research study (i.e., publication of the survey results).
The survey was aimed at the entire population of VA psychia-
trists. Speciﬁcally, we used an informatics-based approach to
identify all actively prescribing psychiatrists in the VA system. In-
formation from several VHA databases were merged and compiled
to assemble an email distribution list for all survey recipients.
Prescribing psychiatrists were surveyed from approximately 129
VAmedical centers and VA healthcare systems across the 50 United
States as well as Puerto Rico. The ﬁnal survey was hosted on Sur-
veyMonkey©. The online survey took approximately 5 minutes to
complete. The CSP Study Director (MHL) emailed 2713 individual
VA psychiatrists inviting them to complete an anonymous online
survey that would help with the planning of a VA Cooperative
Study. The survey was conducted between April 16th and May 16th
of 2012. After the initial email was deployed, two additional
reminder emails were sent to encourage individuals to complete
the survey (see Appendix A for invitational email letter). Therefore,
there were three waves of data collection occurring 9 to 14 days
apart.
2.2. Identifying study population and creating the distribution list
The assembly of 2713 active VA email addresses was the most
labor intensive and time consuming aspect of implementing the
survey. In brief, the VHA Outpatient Encounter ﬁle was used to
identify all physicians who completed encounter forms for outpa-
tient visits to VA Mental Health clinics during Fiscal Year (FY) 2011.
Next, this list was narrowed to the most relevant Provider Type in
the database: Allopathic and Osteopathic Physicians; Psychiatry
and Neurology; Psychiatry providers. Scrambled Social Security
Numbers (SSNs), VA station codes, and names of the selected
providers were retrieved from the Decision Support System (DSS)Providers ﬁle. This list of providers was then merged with the Staff
Table of the Corporate Data Warehouse (CDW) database and the
automated Lightweight Directory Access Protocol (LDAP) lookup
system was used to retrieve email addresses for all providers.
Finally, duplicates were manually checked and records that had
missing or obviously wrong position titles (e.g., incorrect provider
type, non-MDs) and/or non-VA addresses were excluded from the
ﬁnal list. Psychiatry Residents and Fellows were included in the
ﬁnal list of providers. The total number of psychiatry providers
identiﬁed using the VHA databases was validated against the
number identiﬁed by the VA Ofﬁce of Mental Health. The resultant
list was inserted into the blind CC portion of email so that each
individual got a personal letter without disclosing the addressees of
other recipients.
2.3. Data collection
The ﬁnal survey was hosted on SurveyMonkey© (https://www.
surveymonkey.com/). This platform records all survey responses
as well as the precise time (EST) that the online survey was
completed. SurveyMonkey© has the capability of analyzing data
online in real time as responses are accumulating. It is also possible
to export the data ﬁle to analyze the responses using statistical
software of one's choice.
3. Results
A total of 2713 email invitation letters were sent and online
survey responses were received from 862 psychiatrists at VA
medical centers across the United States. Overall, the response rate
after three waves each 9 to 14 days apart was 31.8%. Among re-
spondents, the response rate for individual items ranged from 98.0
to 99.9% with one exception: only 34.3% of respondents provided
their three digit VA station code. Fig. 1 shows the frequency of
survey response over time. The best response rate occurred on the
ﬁrst day the survey opened (n ¼ 297). The response after the ﬁrst
email reminder (Wave 2, Day 1) was also very strong (n ¼ 177).
However, by the third email reminder (Wave 3, Day 1), the re-
sponses tapered off considerably (n ¼ 61).
The ﬁrst goal of the survey was to understand current experi-
ence and practice with respect to lithium usage (see Appendix A,
Questions 2 and 3). As shown in Table 1, 93.3% of the responders
currently prescribed lithium for patients with bipolar disorder and
72.7% for patients with major depression who did not respond to
antidepressants. Among respondents who reported currently pre-
scribing lithium for bipolar disorder, approximately three-quarters
(73.9%) prescribed lithium for 10 to 50% of their patients with bi-
polar disorder. Among respondents who endorsed currently
Table 1
VA psychiatrists' report of lithium use for the treatment of bipolar disorder and treatment-resistant major depression.
Response options Prescribe lithium for bipolar disorder, n (%) Prescribe lithium for treatment-resistant major depression, n (%)
Yes 804 (93.3%)a 625 (72.7%)c
Rarely (<10% of patients) 115 (14.3%)b 377 (60.3%)d
Occasionally (10e25% of patients) 309 (38.4%)b 215 (34.4%)d
Fairly often (25e50% of patients) 285 (35.4%)b 31 (5.0%)d
Very often (>50% of patients) 95 (11.8%)b 2 (0.3%)d
Note: Superscripts denote total numbers of respondents used as the denominators to calculate the percentages for each response option: a ¼ 862, b ¼ 804, c ¼ 860, d ¼ 625.
K.M. Harrington et al. / Contemporary Clinical Trials Communications 4 (2016) 149e154 151prescribing lithium for major depression, the majority (60.3%) re-
ported prescribing lithium only rarely (i.e., <10% of patients with
major depression who had not responded to antidepressants).
The second goal of the survey was to determine whether VA
psychiatrists would be willing to randomize their patient into the
proposed study and endorse the study design (see Appendix A,
Question 6). The major assumptions of the study designwere given
and respondents were asked: “Would you refer such a patient to a
randomized, double-blind, placebo-controlled study of adjunctive
lithium treatment for suicide prevention? (Lithiumwill be carefully
monitored),” and 74.2% answered “Yes”, 16.8% were unsure, and
8.9% answered “No”.
The third goal was to determine what effect size would be
considered large enough to inﬂuence prescribing behavior among
practicing psychiatrists (see Appendix A, Question 7). Respondents
were asked, “What overall percentage of reduction in suicide at-
tempts would convince you to prescribe lithium for your own pa-
tient after a recent attempt?” Options between 10 and 100% were
given in 10% increments. Fig. 2a displays the distribution of raw
responses to the effect size question. The option of “need more
information” was selected by 18.5% of respondents. Another 17.8%
of respondents said they would be convinced to prescribe lithium
for suicide prevention if a randomized controlled trial found a 50%
reduction in suicide reattempts, followed by 17.4% who endorsed a
30% reduction in suicide reattempts. Among those who selected a
numerical response (n ¼ 690), the largest number of respondents
(21.9%) selected a 50% reduction, 21.3% selected a 30% reduction,
and 19.6% selected a 20% reduction. Fig. 2b shows the distribution
of cumulative response percent for the subset of numerical
response options in ascending order from 10 to 100%. Taken
together, over half of respondents (61%) would prescribe lithium if
it reduced suicide attempts by at least 40% and an even greater
majority (83%) if it reduced suicide attempts by at least 50%.Fig. 2. a. VA psychiatrists' opinions about the reduction in suicide reattempts that
would be needed to change prescribing practice (distribution of raw response percent).
b. VA psychiatrists' opinions about the reduction in suicide reattempts that would be
needed to change prescribing practice (cumulative distribution of response percent).4. Discussion
During the planning phase of CSP#590 (Liþ), experts and con-
sultants could not reach consensus on two key issues. First, it was
unclear whether the proposed study had sufﬁcient support in the
ﬁeld to warrant the large expenditure of resources needed to
conduct the trial. Second, there was uncertainty about what effect
size would be large enough to change prescribing behavior among
practicing clinicians. The results of the survey helped to resolve
these concerns and we believe played an important role in the
study sponsor's funding decision.
This survey was completed by 862 psychiatrists at more than
107 VA medical centers across the United States. The overall
response rate for the survey was 31.8%. The best response rate
occurred on the ﬁrst day the survey opened; however, there were
additional surges immediately following reminder emails albeit
with diminishing returns (see Fig.1). Littlewas gained by allowing a
longer interval between reminders as indicated by the relatively
ﬂat line from day three onward. This response pattern is consistent
with other online surveys which have found that reminder noticesare associated with higher response rates but there are diminishing
returns with larger numbers of contacts (see meta-analysis [6]).
Although reported response rates for online surveys range widely
from 5 to 85% [7], our response rate of 31.8% is consistent with the
average rate achieved in online surveys (mean ¼ 33% and 35%, re-
ported in two meta-analyses [6,7] respectively). Notably, the meta-
analyses included diverse types of online surveys that were con-
ducted in a variety of ﬁelds such as medicine, management, market
research, policy research, education, and telecommunication.
Compared with a review of internet-based surveys of health pro-
fessionals in the United States which reported response rates
ranging from 9 to 75% (n¼ 8; mean¼ 45%) [8], our survey response
rate fell in the middle of this range.
The ﬁrst goal of this provider survey was to understand current
experience and practice with lithium among VA prescribing
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for treating bipolar disorder (93%) as well as treatment-resistant
major depressive disorder (73%). Our survey shows that currently
(as of 2012), themajority of VA psychiatrists report they use lithium
in 10 to 50% of their patients with bipolar disorder and in less than
10% of individuals with refractory depression (see Table 1 for
complete breakdown of responses). We compared the psychiatrists'
reports on their use of lithium with contemporaneous pharmacy
data from the VA's Serious Mental Illness Treatment Resource and
Evaluation Center (SMITREC), a program evaluation center in the
VA Ofﬁce of Mental Health Operations. SMITREC examined outpa-
tient lithium prescription rates among VHA patients with a recor-
ded diagnosis of bipolar disorder in FY2013 and outpatient lithium
receipt was observed for 14.8% of patients. Among individuals with
a bipolar disorder diagnosis in FY2013 who had utilized VHA ser-
vices in at least three of the prior ﬁve ﬁscal years, the prevalence of
outpatient lithium receipt in the six-year period FY2008 e FY2013
was 26.5% (J.F. McCarthy, personal communication, September 29,
2014). These data suggest that a signiﬁcant subset of survey re-
spondents endorsed higher rates of lithium prescription than re-
ﬂected in VHA pharmacy records. Differences in providers' reported
prescription patterns relative to prescription rates in the VHA
pharmacy records may be partially attributed to provider factors
such as individual provider decision-making and geographic
regional variation affecting medication choices [9], as well as
response bias.
By comparison, a non-VA study analyzed utilization rates for
psychotropic drugs using computerized medical beneﬁts data from
2002 to 2003 in the United States and found that lithium was
prescribed as an initial monotherapy in only 7.5% of individuals
diagnosed with bipolar disorder [10]. Despite an overall trend of
declining use of lithium for the treatment of bipolar disorder in the
United States [11], our survey results suggest that a majority of VA
psychiatrists continue to prescribe lithium for appropriate patients
with bipolar disorder on a regular basis (i.e., occasionally to fairly
often). Furthermore, SMITREC's analysis of VHA pharmacy records
provides corroborative evidence that lithium prescription rates
among VA providers appear to be at least double that of the overall
rate in the United States (14.8% vs. 7.5%). Proponents of lithium have
argued that the pattern of underutilizing lithium (despite its
proven efﬁcacy in the treatment of bipolar disorder) may be due in
part to the abundance of marketing efforts for newer FDA-approved
drugs, combined with concerns regarding adverse effects, tolera-
bility, and the perception that regular toxicity monitoring is difﬁ-
cult [11,12]. Indeed, a recent analysis of VA administrative data for
Veterans diagnosed with bipolar disorder from 2003 to 2010
demonstrated that second-generation antipsychotics have sup-
planted lithium, valproate, and carbamazepine/oxcarbazepine as
frontline antimanic treatment for bipolar disorder [9].
The second goal was to see whether psychiatrists would be
supportive of randomizing their patients to lithium or placebo and
endorse the study design. Three out of four respondents indicated
that they would refer their patients who had recently survived a
suicide attempt to the proposed randomized controlled trial. This
result suggested very good ﬁeld support for implementing a ran-
domized, double-blind, placebo-controlled study of adjunctive
lithium treatment for suicide prevention. Furthermore, the results
helped to conﬁrm that the research question is clinically important
and compelling to the potential end-users of the trial.
The third objective was to determine what effect size would be
considered large enough to inﬂuence prescribing behavior among
practicing psychiatrists. Sixty-one percent of respondents would
prescribe lithium if it reduced subsequent suicide attempts by at
least 40% and 83% if it reduced reattempts by at least 50%. These
survey ﬁndings provided additional support for the hypothesizedeffect size which was based on conventional methods of effect size
estimation (i.e., a weighted average of effects observed in published
lithium studies). Speciﬁcally, based on an effect size of approxi-
mately 43% observed in previous lithium studies and allowing for
attenuation due to non-adherence, the CSP#590 study design is
powered to detect an effect of 37% or greater reduction in the one-
year rate of repeated suicide attempts. Thus, these survey ﬁndings
lend support to the effect size used for this trial design and suggest
that this is a clinically meaningful effect size that would convince a
majority of psychiatrists to change their practice to prescribe
lithium for appropriate patients with bipolar disorder or treatment-
resistant major depression who have a survived a suicide attempt.
The estimation of an a priori sample size on which to plan a
rigorous clinical trial has had relatively little study and discussion
but is a critical step in trials planning. The usual gambits for esti-
mating an effect size include using observed differences from
previous trials, expert opinions, or when in doubt, the usual 20%
difference. Reﬂecting this ad hoc approach are the varied terms to
describe its designation: minimal clinically important difference,
meaningful difference, clinically worthwhile difference, minimum
responsiveness, et cetera. In this survey, we reasoned that the
consumers or users of trials information are either the patient and/
or the clinicians who treat persons with the condition (in this
example, individuals with mood disorders at potential suicide risk)
and they are best qualiﬁed to state what treatment difference
would inﬂuence their practice and how likely it would be changed.
To the best of our knowledge, this represents the ﬁrst survey of
clinicians' beliefs conducted during the planning of a VA Coopera-
tive Study with the primary goal of informing sample size estimates
as well as gauging ﬁeld support. Several other research groups have
administered structured questionnaires to elicit expert opinions
and gather a priori information for the purpose of informing trial
design and sample size estimates, including assessing the level of
treatment beneﬁt that was deemed to be sufﬁcient for causing
clinicians to change their practice [13e15]. This approach empha-
sizes an important but sometimes overlooked aim of clinical trials,
speciﬁcally that the product of a clinical trial should not be merely
to establish treatment differences, but should be to meaningfully
inﬂuence medical practice [13].
4.1. Limitations and conclusions
This method has several limitations that deserve comment,
some of which are inherent to any survey. First, the survey was
emailed and may be associated with lower response rates than
mailed versions [7,16,17]. Nonetheless, the resources required to
deploy an internet survey are considerably less than traditional
paper-based mail surveys. The design and implementation of the
current survey was carried out over several weeks and at little cost.
Furthermore, using personalized correspondence and follow-up
reminders proved to be effective in boosting the overall survey
response rate, a ﬁnding which is consistent with previous studies
[6,8].
Second, potential response bias of responders and non-
responders cannot be inferred because the survey was completely
anonymous. Responders may differ from non-responders and limit
the generalizability of the results to the entire population of VA
psychiatrists. Response bias arguably could go in either direction
but responses generally indicated that the majority of respondents
were supportive of the trial. The anonymity of the survey also
precludes the possibility of fully evaluating the representativeness
of survey responses. However, one indicator of sample represen-
tativeness is the range of participation by providers at different VA
medical centers. Providers could volunteer their site code on the
survey and 34% (n ¼ 295) of respondents provided their three digit
Fig. 3. Geographic distribution of survey respondents who reported VA station code (n ¼ 295).
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that survey participants represented 107 unique VA medical cen-
ters from 44 U.S. states as well as Puerto Rico (see Fig. 3 which
depicts the geographic distribution of survey responders). Among
those who reported station codes, there were no conﬁrmed re-
spondents from the following states: Alaska, Kentucky, Maine, New
Hampshire, North Dakota, and Utah. Given that only a third of re-
spondents provided valid station codes, we do not have a full pic-
ture of how representative respondents are of the whole VA
population. However, it is reassuring that the survey results reﬂect
the opinions of psychiatrists from a large number of VA medical
centers across a large majority of the United States, and the
geographical distribution of respondents appears to generally
correspond with the volume of Veterans served by various VA fa-
cilities. A related drawback of conducting an anonymous survey
was that we could not know the identity of responders or non-
responders and we therefore sent reminder emails to the entire
distribution list rather than only targeting the non-responders.
Third, the primary rate- and time-limiting step was assembling
a distribution list of appropriate clinicians from available data
sources. It highlighted the fact that comprehensive lists of pro-
viders by specialties are not always available. We estimated
50 hours were required to assemble the target population based on
the providers' specialty (psychiatry), credentials (medical degree),
position title, and valid VA email address for physicians involved in
providing mental health services. For future studies, access to a
national listserv for VA providers in the specialty of interest (if
available) would be a much more efﬁcient method of reaching the
target population.
Finally, what clinicians say they would do in hypothetical situ-
ations might not reﬂect actual behavior. Conﬁdentiality may in-
crease reliability in sensitive topics where respondents might feeljudged and possibly increase response rate. In conclusion, even
with the limitations of potential response bias and the reliability of
responses on future prescribing behavior, a survey of targeted users
of a trial's results may add a convenient, empirical method to the
standard ways of estimating and justifying clinically relevant effect
sizes for clinical trials.
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